drugset
drugset / Trial / NCT03855696

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

NCT03855696 ↗

Phase 1 Completed 41 enrolled Green Cross Corporation Dream CIS, Inc. · collab
RandomizedSequentialDouble-blindPrevention

Summary

The purpose of this study is to assess the safety and tolerability of MG1113 in the single ascending dose study (IV injection or SC injection) in healthy subjects and hemophiia patients.

Timeline

Start
2019-01-21
Primary completion
2021-06-30
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MG1113 Protein / enzyme biologic 0.5 mg/kg Subcutaneous
Subject MG1113 Protein / enzyme biologic 1.7 mg/kg Subcutaneous
Subject MG1113 Protein / enzyme biologic 3.3 mg/kg Subcutaneous

Indications

hemophilia